Combining innovative science, leading technology, and unmatched know-how to create novel medicines.
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
Our Science
Our lead program targets interleukin-11, a cytokine which is a central mediator of fibrosis and plays a key role in the tumor microenvironment of certain cancers.
Our Pipeline
Lassen is applying industry-leading antibody technologies to create a pipeline of breakthrough therapeutics.
Our team has a proven track record of building robust antibody development platforms and pipelines and is guided by a set of meaningful and inspirational core values. We are:
- Innovative and adapt to challenges
- Honest and communicate transparently
- Collaborative and treat everyone with respect
- Focused on people – our team, our collaborators, and patients
- Passionate about creating life-improving medicines
-
- Inhibition of signaling through IL-11R with LASN01 offers a potential novel treatment for idiopathic pulmonary fibrosis and other fibro-inflammatory diseases
-
- Lassen to also be featured at the ATS Respiratory Innovation Summit
-
04 May 2023 | Lassen Therapeutics Appoints Maria Fardis, PhD, MBA, as Chief Executive Officer
- Industry veteran Dr. Fardis to succeed current CEO Mark Barrett to lead Lassen in its next phase of growth and ongoing advancement of clinical programs